pp-237 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Advanced Breast Cancer (ER+), Lung Cancer / Clinical stage: Phase 3 / Modality: Small molecule histone deacetylase (HDAC) inhibitor (class I selective) / Mechanism & Target: Class I HDAC inhibitor for epigenetic modulation / Route & form: Oral / Differentiation: First HDACi with positive randomized Phase 2 in breast cancer; Breakthrough Therapy designation
Manufacturer #39441
| Clinical-stage oncology biopharmaceutical company developing epigenetic cancer therapies. Advances a selective histone deacetylase inhibitor with Breakthrough Therapy designation for breast cancer. Progresses Phase 3 pivotal development through global clinical collaboration. |
None